PTN News Release: AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

By 23Scadoo, January 9, 2017

Leave a Reply

1 Comment on " PTN News Release: AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder"

avatar

dcsorg
Irregular
dcsorg

Why is AMAG down $12.60 on minor news? Any insight on this issue. I have been watching this stock and considering buying, is there more to the issue. Could it be manipulation by larger players. Down 35% it a bit extreme. Any ideas.

wpDiscuz